In this article
FDA Approval of Zusduri for Recurring Bladder Cancer
On June 12, 2025, the Food and Drug Administration approved mitomycin intravesical solution (Zusduri, UroGen Pharma) for adults with recurring low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
ENVISION Clinical Trial Design and Methodology
The efficacy was assessed in ENVISION (NCT05243550), a single-arm, multicenter trial involving 240 adults with low-grade NMIBC that recurred following previous transurethral resection of bladder tumor (TURBT) and satisfied 1-2 of the subsequent criteria: multiple tumors, a solitary tumor exceeding 3 cm, and recurrence within one year. Patients were administered 75 mg of mitomycin as an intravesical solution once weekly for a duration of 6 consecutive weeks. Evaluation of tumor status was conducted every three months using cystoscopy, targeted biopsy, and urine cytology.
The primary efficacy outcomes were complete response (CR) at three months and duration of response (DOR). Complete remission (CR) was defined as the absence of detectable disease in the bladder as determined by cystoscopy and urine cytology. If necessary, we conducted a biopsy. Of the 223 patients assessed for response, 78% (95% CI: 72, 83) achieved a complete response (CR). The duration of response (DOR) varied from 0 to over 25 months, with 79% of patients who responded maintaining their response for a minimum of 12 months.
The common side effects (occurring in 10% or more of patients) included high creatinine levels, high potassium levels, painful urination, low hemoglobin, high aspartate aminotransferase, high alanine aminotransferase, increased eosinophils, decreased lymphocytes, urinary tract infections, low neutrophils, and blood in urine. 12% of individuals experienced severe adverse responses, including urine retention (0.8%) and urethral stenosis (0.4%). One patient experienced a fatal adverse event resulting in heart failure.
The advised dosage of mitomycin is 75 mg (56 mL), administered weekly for six weeks into the bladder with a urinary catheter.
How CancerFax Helps
CancerFax is a specialist cancer access and patient-navigation platform. We help patients and families understand their options, organise medical records, coordinate hospital communication, and support cross-border treatment planning where appropriate.
We help collect and organise reports, scans, pathology, biomarker results, and treatment history for structured case review.
We communicate with hospitals or trial teams to assess whether a case may be suitable for further screening.
We support appointment coordination, document submission, translation, and direct communication with international departments.
For international patients, we help with practical coordination — travel planning, hospital admission guidance, and local support.
If this option is not suitable, we help explore other relevant treatments, clinical trials, or advanced care pathways.
From inquiry through to follow-up, our coordinators provide a single point of contact for the family.
CancerFax does not guarantee treatment access, eligibility, or clinical outcome. Our role is to help patients access accurate information, structured review, and appropriate specialist pathways.
About Dr. Nishant Mittal
Dr. Nishant Mittal is a highly accomplished researcher with over 13 years of experience in the fields of cardiovascular biology and cancer research. Significant contributions to stem cell biology, developmental biology, and innovative research techniques mark his career. Research Highlights Dr. Mittal's research has focused on several key areas: 1) Cardio…
✓ Reviewed for medical accuracy by the CancerFax review panel.
Medical Disclaimer
This article is for educational purposes only and should not replace medical advice, diagnosis, or treatment from a qualified oncology specialist. Every patient's case is different. Treatment decisions should always be made after a review of complete medical records by the treating medical team.
Treatment availability, eligibility, timelines, and access can change. Any clinical trial participation depends on detailed review and approval by the trial hospital or investigator.